Unaudited Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive (loss) income	Accumulated deficit	Noncontrolling interests
Beginning balance (in shares) at Dec. 31, 2022	8,700,885
Beginning balance at Dec. 31, 2022	$ 107,808
Convertible preferred stock
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)	(8,700,885)
Conversion of convertible preferred stock and non-controlling interests to common stock	$ (107,808)
Ending balance (in shares) at Mar. 31, 2023	0
Ending balance at Mar. 31, 2023	$ 0
Beginning balance (in shares) at Dec. 31, 2022		2,217,737
Beginning balance at Dec. 31, 2022	(142,670)	$ 2	$ 1,197	$ (41)	$ (158,223)	$ 14,395
Stockholders' Equity (Deficit)
Stock-based compensation	265		265
Unrealized gain on marketable securities	177			177
Issuance of common stock for cash in pre-closing financing (in shares)		3,730,608
Issuance of common stock for cash in pre-closing financing	30,640	$ 4	30,636
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)		5,059,338
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability	42,447	$ 5	42,442
Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)		10,374,272
Issuance of common stock to Sesen Bio shareholders in reverse capitalization	72,044	$ 10	72,034
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)		18,872,711
Conversion of convertible preferred stock and non-controlling interests to common stock	107,809	$ 19	122,185			(14,395)
Net loss	(24,642)				(24,642)
Ending balance (in shares) at Mar. 31, 2023		40,254,666
Ending balance at Mar. 31, 2023	$ 86,070	$ 40	268,759	136	(182,865)	0
Beginning balance (in shares) at Dec. 31, 2023	0
Beginning balance at Dec. 31, 2023	$ 0
Ending balance (in shares) at Mar. 31, 2024	0
Ending balance at Mar. 31, 2024	$ 0
Beginning balance (in shares) at Dec. 31, 2023		40,609,915
Beginning balance at Dec. 31, 2023	$ 26,532	$ 40	271,594	0	(245,102)	0
Stockholders' Equity (Deficit)
Exercise of stock options (in shares)	1,579	1,579
Exercise of stock options	$ 2		2
Stock-based compensation	1,057		1,057
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)		931,250
Sale of common stock under Open Market Sales Agreement, net of issuance costs	2,282	$ 1	2,281
Unrealized gain on marketable securities	0
Net loss	(18,978)				(18,978)
Ending balance (in shares) at Mar. 31, 2024		41,542,744
Ending balance at Mar. 31, 2024	$ 10,895	$ 41	$ 274,934	$ 0	$ (264,080)	$ 0